Vermittlung von Wissenschaftsverständnis in der Grundschule

Der Beitrag ist darauf angelegt, jeweils einen Ansatzpunkt zur Optimierung von Erziehungsanstrengungen zu benennen und die Wirksamkeit der vorgeschlagenen Maßnahmen empirisch zu belegen ... . Die Studie untersucht Vorstellungen über die Grundlagen des Experimentierens und das Wissenschaftsverständnis bei Grundschülern. Dabei wird in einem ersten Schritt das intuitive Wissenschaftsverständnis von Schülern der dritten und vierten Jahrgangsstufe beschrieben und durch kurze Interventionen überprüft, in welchem Ausmaß die epistemologischen Präkonzepte durch die Anregung wissenschafts- bzw. erkenntnistheoretischer Reflexion anregbar sind. Im zweiten Schritt wird geprüft, ob reflektiertes Wissenschaftsverständnis für den Erwerb inhaltlichen naturwissenschaftlichen Wissens förderlich ist. (DIPF/Orig.

Safety and performance of a novel cerebral embolic protection device for transcatheter aortic valve implantation: the PROTEMBO C Trial

Background: Stroke remains a feared complication associated with transcatheter aortic valve implantation (TAVI). Embolic cerebral injury occurs in the majority of TAVI cases and can lead to cognitive dysfunction. Aims: The PROTEMBO C Trial evaluated the safety and performance of the ProtEmbo Cerebral Protection System in TAVI patients. Methods: Forty-one patients were enrolled in this single-arm study conducted at 8 European centres. The primary safety endpoint was the rate of VARC 2-defined major adverse cardiac and cerebrovascular events (MACCE) at 30 days; the primary performance endpoint was the composite rate of technical success versus performance goals (PG). Secondary endpoints included brain diffusion-weighted magnetic resonance imaging (DW-MRI), new lesion volume, and the rate of death or all strokes compared to historical data. Results: Thirty-seven of 41 enrolled patients underwent TAVI with the ProtEmbo device (intention-to-treat [ITT] population). Both primary endpoints were met. MACCE at 30 days was 8.1% (upper limit of the 95% confidence interval [CI]: 21.3% vs PG 25%; p=0.009), and technical success was 94.6% (lower limit of the 95% CI: 82.3% vs PG 75%; p=0.003). New DW-MRI lesion volumes with ProtEmbo were smaller than in historical data, and 87% of patients completing MRI follow-up had no single lesion >150 mm(3). There was 1 stroke in a patient in whom the device was removed prematurely before TAVI completion. Conclusions: The PROTEMBO C Trial met its primary safety and performance endpoints compared to prespecified historical PGs. Patients had smaller brain lesion volumes on DW-MRI compared to prior series and no larger single lesions. These results warrant further evaluation of the ProtEmbo in a larger randomised controlled trial (RCT)

Migrating the Belle II collaborative services and tools

The Belle II collaboration decided in 2016 to migrate its collaborative services and tools into the existing IT infrastructure at DESY. The goal was to reduce the maintenance effort for solutions operated by Belle II members as well as to deploy state-of-art technologies. In addition, some new services and tools were or will be introduced. Planning and migration work was carried out by small teams consisting of experts form Belle II and the involved IT divisions. The migration was successfully accomplished before the KEK computer centre replacement in August 2016